AlphaRx Provides Corporate and Development Update
Hong Kong, March 16 – AlphaRx Inc. (OTC BB:ALRX), today provided an update on its internal product candidates and development plans.
Highlights of the Company’s product review and upcoming corporate milestones include:
* Over the last 12 months we have made significant progress in moving ARX8203 toward clinical application. ARX8203, a novel prodrug of a FDA [...]
AlphaRx Provides Update on Indaflex
Hong Kong, May 10, 2010 (MARKETWIRE) — AlphaRx, Inc. (OTCBB: ALRX), has been advised by Cypress Biosciences (“Cypress”), its development partner for Indaflex, that Cypress is not funding development of Indaflex. Notwithstanding the termination of all Indaflex activity in the U.S.A., AlphaRx continues to develop Indaflex for the Chinese market. AlphaRx is working diligently with [...]
AlphaRx Plans to List Subsidiary
Companies need to periodically consider actions that unlock their intrinsic value. At this point in time, AlphaRx is pursuing such an opportunity.
Hong Kong, March 29, 2010 (MARKETWIRE) — AlphaRx, Inc. (OTCBB: ALRX) today announced that the Company plans to list its’ Canadian subsidiary, which has been focused on China and emerging markets, on a Canadian [...]
AlphaRx and Gaia BioPharma Secure Phase I/II Manufacturer for GAI-122 and Unveil Their Clinical Development Strategy
HONG KONG — (MARKET WIRE) — 01/21/10 AlphaRx Inc. (OTCBB: ALRX) announced today that its licensee, Gaia BioPharma Limited, has signed an agreement with a contract manufacturing organization (CMO) to manufacture GAI-122 for use in the planned Phase I and II clinical trials of that product candidate. GAI-122 is being developed as I.V. administered formulation [...]
